Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 221

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 221
---
 in any meeting of the holders of Common Stock, except as provided in
the Series E Certificate of Designations (or as otherwise required by applicable law).

Covenants. The Series
E Certificate of Designations contains a variety of obligations on the Company’s part not to engage in specified activities. In
particular, the Company will not, and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or
distribution on any of the Company’s capital stock (other than as required under the Series E Certificate of Designations) and will
not incur any indebtedness other than ordinary course trade payables or, subject to certain exceptions, incur any liens. In addition,
the Company will not issue any preferred stock or issue any other securities that would cause a breach or default under the Series E Certificate
of Designations.

Reservation Requirements.
So long as any Series E Preferred Stock remains outstanding, the Company shall at all times reserve at least 250% of the number of shares
of Common Stock as shall from time to time be necessary to effect the conversion of all Series E Preferred Stock then outstanding.

Registration Rights Agreement

On October 14, 2025, the
Company entered into the Fifth Registration Rights Agreement, pursuant to which the Company will be required to file a registration statement
with the SEC, to register for resale the Common Stock issuable upon the conversion of the Series E Preferred Stock.

Nasdaq Delisting

On October 29, 2025, the
Company received the determination of the Nasdaq Hearings Panel (the “Panel”) to deny the Company’s request to continue
the listing of its shares of common stock on Nasdaq and that the trading in the Company’s securities would be suspended at the open
of trading on October 31, 2025. The Company submitted a request for review of the Panel’s decision by the Nasdaq Listing and Hearing
Review Council. On October 31, 2025, the Company’s shares of common stock commenced trading on the OTC Pink Sheets.

Other

Subsequent to September 30, 2025 and through November 19, 2025, 4,448
shares of Series D Preferred Stock were converted into 7,359,955 shares of Common Stock at conversion share prices ranging from $5.36,
the Series D Adjustment Price, down to $0.05 per share.

Subsequent to September 30, 2025 and through November 19, 2025, the